Biomarker ID 2049 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2049 |
| Biomarker | TSPY |
| Biomarker Name/Symbol (given in Publication) | TSPY |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | classify HCC and LUAD tumors as TCN-active and TCN-silent group and validated on independent dataset |
| Experimental Condition | Normal vs cancer |
| Cancer type | Hepatocellular carcinoma |
| Regulation | upregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 27771326 |
| Type of Biomarker | Diagnostic |
| Pathway | oncogenic pathway |
| Cohort | 137 matched pairs of male tumor and corresponding non-tumor samples including 27 cases of HCC (designated as LIHC in TCGA database), 24 cases of LUAD, 28 cases of HNSC, 10 cases of BLCA, 16 cases of KIRP, 16 cases COAD. Unpaired male tumor samples included 158 HCC cases and 184 LUAD cases. of THCA, |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |